JP2003528609A - バスコスタチンおよび他のニドゲンドメインの抗血管形成特性および抗腫瘍特性 - Google Patents

バスコスタチンおよび他のニドゲンドメインの抗血管形成特性および抗腫瘍特性

Info

Publication number
JP2003528609A
JP2003528609A JP2001570742A JP2001570742A JP2003528609A JP 2003528609 A JP2003528609 A JP 2003528609A JP 2001570742 A JP2001570742 A JP 2001570742A JP 2001570742 A JP2001570742 A JP 2001570742A JP 2003528609 A JP2003528609 A JP 2003528609A
Authority
JP
Japan
Prior art keywords
protein
fragment
angiogenic
cells
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001570742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528609A5 (https=
Inventor
カルリ，ラグラム
Original Assignee
ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド filed Critical ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド
Publication of JP2003528609A publication Critical patent/JP2003528609A/ja
Publication of JP2003528609A5 publication Critical patent/JP2003528609A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
JP2001570742A 2000-03-29 2001-03-28 バスコスタチンおよび他のニドゲンドメインの抗血管形成特性および抗腫瘍特性 Pending JP2003528609A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19287100P 2000-03-29 2000-03-29
US60/192,871 2000-03-29
PCT/US2001/040382 WO2001073025A2 (en) 2000-03-29 2001-03-28 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains

Publications (2)

Publication Number Publication Date
JP2003528609A true JP2003528609A (ja) 2003-09-30
JP2003528609A5 JP2003528609A5 (https=) 2008-05-08

Family

ID=22711364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001570742A Pending JP2003528609A (ja) 2000-03-29 2001-03-28 バスコスタチンおよび他のニドゲンドメインの抗血管形成特性および抗腫瘍特性

Country Status (8)

Country Link
EP (1) EP1268798B1 (https=)
JP (1) JP2003528609A (https=)
AT (1) ATE328081T1 (https=)
AU (1) AU8727401A (https=)
CA (1) CA2403515A1 (https=)
DE (1) DE60120131T2 (https=)
NZ (1) NZ521567A (https=)
WO (1) WO2001073025A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389751A1 (en) * 1999-11-01 2001-05-10 Curagen Corporation Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
CN1455682A (zh) 2001-01-05 2003-11-12 百疗医株式会社 包括编码抗－血管生成蛋白或者其部分的基因的用于类风湿性关节炎的基因治疗的组合物
US7407660B2 (en) 2003-04-16 2008-08-05 Genentech, Inc. Methods and compositions for selective modulation of vascularization

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010063376, ＥＭＢＯ Ｊｏｕｒｎａｌ， １９８９， Ｖｏｌ． ８， Ｎｏ． １， ｐｐ．６５−７２ *
JPN6010063377, Ｄｅｖｅｌｏｐｍｅｎｔａｌ Ｂｉｏｌｏｇｙ， １９９４， Ｖｏｌ． １６４， Ｎｏ． １， ｐｐ． １９７−２０６ *

Also Published As

Publication number Publication date
EP1268798B1 (en) 2006-05-31
DE60120131D1 (de) 2006-07-06
NZ521567A (en) 2004-04-30
WO2001073025A3 (en) 2002-06-27
EP1268798A2 (en) 2003-01-02
ATE328081T1 (de) 2006-06-15
DE60120131T2 (de) 2007-01-04
AU8727401A (en) 2001-10-08
WO2001073025A2 (en) 2001-10-04
CA2403515A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
US5824299A (en) Modulation of endothelial cell proliferation with IP-10
AU749904B2 (en) Restin and methods of use thereof
JP2008301823A (ja) 抗血管形成タンパク質およびその使用方法
US6797488B1 (en) Methods of producing anti-angiogenic proteins
US6759047B1 (en) Anti-angiogenic proteins and methods of use thereof
JP2003528609A (ja) バスコスタチンおよび他のニドゲンドメインの抗血管形成特性および抗腫瘍特性
US20080167227A1 (en) Anti-angiogenic and anti-tumor properties of matin and other laminin domains
AU2001287274B2 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
US20080167232A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other indogen domains
US6852691B1 (en) Anti-angiogenic peptides and methods of use thereof
AU2001287274A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
AU2001245994B2 (en) Anti-angiogenic and anti-tumor properties of matin and other laminin domains
EP1719779A2 (en) Antibodies against Matin
AU2001245994A1 (en) Anti-angiogenic and anti-tumor properties of matin and other laminin domains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110422